Skin Cancer Detection Product, MoleMate, Accounts for Over 60% of Q4 Revenues
MISSISSAUGA, ON, May 7, 2012 /CNW/ - MedX Health Corp., (TSXV: MDX) a global leader in drug free, non-invasive low level laser light therapy and light imaging systems, today announced financial results for the year ending December 31, 2011. Sales showed a strong overall growth of 33%, with a large Q4 contribution from MoleMate. Revenues for fiscal 2011 were $872,584, representing a 33% increase over the revenues of $657,358 in fiscal 2010. Earnings losses were reduced to $868,089 or
.03 per share compared to a loss of $992,574 or
.03 per share for fiscal 2010.
According to this release, revenues were $872,584 and losses were $868,089 for the whole of 2011. Now see calculation below:
Revenues - Losses = $872,584 - $868,089 = $4,495
As well, the news release mentions that revenues were 33% higher for all of 2011 when compared to 2010 and that losses were reduced from $992,574 to $868,089. As an investor, that is what I like to see. Revenues on the increase and losses on the decline.
Please let me know if I am missing something. Thank you.
Regards,
sanman2012